

**ARIZONA DEPARTMENT OF CORRECTIONS
DIRECTOR'S OFFICE**

MEMORANDUM

TO: **DISTRIBUTION**

FROM: **CHARLES L. RYAN**

DATE: August 15, 2017

SUBJECT: Director's Instruction # 356, Use of NARCAN Nasal Spray for Opioid Drug Overdoses

This Director's Instruction is effective immediately and will remain in effect until incorporated into the appropriate Department Order.

PURPOSE:

This Director's Instruction provides trained ADC correctional series staff with guidelines to utilize NARCAN Nasal Spray in order to effectively treat and reduce fatal opiate/opioid overdoses. NARCAN Nasal Spray is not effective on individuals who have used non-opioid drugs including benzodiazepines (e.g., Xanax, Klonopin, Valium, etc.) bath salts, cocaine, alcohol or methamphetamines.

PROCEDURES:

- 1.1 Wardens and Deputy Wardens shall ensure all correctional series staff are trained in the use of, and authorized to administer NARCAN Nasal Spray in the case of a suspected opioid overdose.
 - 1.1.1 NARCAN Nasal Spray kits shall be stored in housing unit control rooms in a secured container with cut down shears. The secured containers red tag number shall be recorded in the post log at the beginning and end of each shift
 - 1.1.2 Staff shall report missing or damaged NARCAN Nasal Spray kits directly to an immediate supervisor and on an Information Report, Form 105-2.
 - 1.1.3 The unit Chief of Security shall be responsible for the unit NARCAN Nasal Spray inventory, reissue and reordering. The unit Chief of Security shall maintain a log containing the location, quantity and expiration date of each NARCAN Nasal Spray device.
 - 1.1.4 The Complex Duty Officer or designee shall be notified immediately of each NARCAN nasal spray use.
- 1.2 Correctional staff shall follow protocols outlined in their NARCAN Nasal Spray training.

- 1.2.1 Correctional staff shall utilize the Incident Command System and notify the shift supervisor of the potential overdose and intended NARCAN Nasal Spray administration.
- 1.2.2 Upon arrival of medical response, notify them why opioid overdose is suspected and the actions taken to reverse the overdose, to include, the quantity of NARCAN Nasal Spray administered.
- 1.3 If NARCAN Nasal Spray is administered to an inmate whose condition was not caused by an opioid overdose, the drug will have no negative effect.
- 1.4 When NARCAN Nasal Spray is administered to an inmate who subsequently tests positive for opioid use by urinalysis or blood tests, the inmate shall be liable for the full cost of the NARCAN Nasal Spray administered. Restitution proceedings shall be conducted in accordance with Department Order #803, Inmate Disciplinary Procedure.

IMPLEMENTATION:

All correctional series staff shall complete Naloxone/NARCAN Nasal Spray training within 60 calendar days of the effective date of this Directors Instruction.

DEFINITIONS:

Naloxone Hydrochloride: An opioid receptor antagonist and antidote for opioid overdose produced in intramuscular, intranasal and intravenous forms. NARCAN is the brand name for Naloxone.

NARCAN Nasal Spray: A pre-filled, single dose intranasal spray used to reverse the effects of an opioid overdose.

Opiates: Naturally derived from the poppy plant, such as heroin and opium.

Opioids: Synthetic opiate drugs such as fentanyl, morphine, buprenorphine, codeine, hydromorphone, hydrocodone, oxymorphone, methadone and oxycodone.

Opioid Overdose: An acute condition, including but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression coma, or death resulting from the consumption or use of an opioid or another substance with which an opioid was combined, or that a layperson would reasonably believe to be an opioid-related drug overdose that requires medical assistance.

CROSS- REFERENCE INDEX:

Department Order # 803, Inmate Disciplinary Procedure

AUTHORITY:

A.R.S. § 36-2228, Administration of opiate antagonists; training; immunity; designation by director

{Original Signature on File}